Optimizing Small Molecule Drug Discovery
The eBook "Optimizing Small Molecule Drug Discovery" addresses the escalating costs and pressures in drug discovery by presenting strategies and technologies to ensure trustworthy, traceable data, enhance productivity and collaboration, accelerate research, and reduce technical debt and overall costs.
The cost of drug discovery is higher than ever. With rising pressure to do more with less, companies need to adopt processes and technologies that will help them drive innovation while controlling costs.
In this eBook you will learn how to overcome common challenges in small molecule drug discovery ultimately allowing you to:
- Ensure data is trustworthy and traceable
- Improve productivity and collaboration
- Speed up research
- Reduce technical debt and total cost of ownership
Related
Addressing Inefficient R&D Workflows
The blog discusses how legacy, fragmented R&D systems hinder innovation in complex, multi-domain scientific research by creating silos and inefficiencies, and presents Dotmatics’ unifying platform as a comprehensive solution that integrates diverse tools, data, and teams to enable smarter collaboration, governed data use, and AI-driven automation for faster, more rigorous innovation.
How Luma Lab Connect Automates Lab Data Acquisition Across 100+ Instruments
Dotmatics Luma Lab Connect, part of the Dotmatics Luma multimodal scientific R&D platform, automates and streamlines the acquisition, management, and preparation of complex, multimodal lab data from over 100 diverse instruments and sources, addressing challenges of data security, integrity, and usability to enhance research productivity and enable FAIR data practices within a unified, low-code SaaS environment.
Data Evolution in Pharma: The Spread of Multimodal
The pharmaceutical industry is shifting from single-mode to multimodal drug discovery, incorporating diverse therapeutic modalities like biologics, gene therapies, and small molecules, but this evolution presents significant challenges in integrating heterogeneous R&D data and technologies, necessitating advanced, compatible platforms to enable efficient collaboration and leverage AI-driven insights for faster, cost-effective drug development.
Le cahier de laboratoire électronique pour l'entreprise, conçu par des scientifiques pour les scientifiques
Le cahier de laboratoire électronique (ELN) de Dotmatics, conçu par des scientifiques pour des scientifiques, offre un cadre intuitif et sécurisé permettant de capturer, stocker, rechercher et partager divers types de données expérimentales (molécules, réactions, séquences, images, vidéos, texte, données numériques) via des protocoles flexibles, des tableaux de bord intelligents, une intégration avec d'autres applications Dotmatics, et un hébergement cloud favorisant la collaboration interne et externe tout en protégeant rigoureusement la propriété intellectuelle.
Arkema Selects Dotmatics for R&D Digitalization Project
Arkema has selected Dotmatics to implement a unified electronic laboratory notebook (ELN) across its French research sites, involving 800 users over five years, to digitalize and secure diverse R&D workflows, enhance data access and continuity, accelerate chemical and material innovation through advanced analytics and AI, and facilitate internal and external collaboration.
NBC News: How AI is Transforming Drug Discovery
In an NBC News segment, Alister Campbell, VP of Dotmatics, explains how the company leverages AI to analyze large datasets, predict effective drug compounds, and streamline fragmented data systems and manual workflows, thereby accelerating and improving the efficiency of drug discovery.